NCT04713371: A Phase 2 Trial for Patients With Metastatic Solid Cancer

NCT04713371
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with bone metastasis as the only site of disease
https://ClinicalTrials.gov/show/NCT04713371

Comments are closed.

Up ↑